Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT04737408

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Bjarne Linde Noergaard (from the registry)
Registry
  • NCT NCT04737408
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04737408. Randomized; no masking; primary purpose prevention. Start 2020-05-13 (actual); primary completion 2023-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study)
Acronym
FlowPromote
Intervention (Drug)
Rosuvastatin 40mg
Lead sponsor
Bjarne Linde Noergaard (class: other)

Record details

Record id
cardio:ct-nct04737408
Content hash
b6acca96ea1521bee3397eb7d7f507a29d8f6c115bde9146e6423675a3256c48